^
Association details:
Biomarker:MAGEC1 expression
Cancer:Multiple Myeloma
Drug:bortezomib (Proteasome inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

ASSESSMENT OF THE EFFICACY OF BORTEZOMIB-CONTAINING THERAPY REGIMENS DEPENDING ON MAGE-C1 GENE EXPRESSION IN MULTIPLE MYELOMA PATIENTS

Published date:
05/12/2022
Excerpt:
Anti-tumor ≥partial response (PR) was achieved in 52, refractory to bortezomib MM was found in 16 patients….The probability of achieving ≥PR in patients with normal MAGE-C1 gene expression was 87.8% and in patients with increased expression- 72.8%. The median time to achieve ≥PR in patients with an expression value ≤0.06 (2ΔCt) was 1.77 months, and in patients with an expression >0.06 (2ΔCt) was 3.06 months, p=0.03 (Fig. 1)....In a single-factor analysis, we were able to determine that patients with normal MAGE-C1 gene expression were significantly more likely to achieve an overall response (≥PR) compared to patients whose MAGE-C1 gene expression was increased. Achievement of ≥PR on bortezomib-containing therapy regimens was documented twice as fast in patients with normal expression of the investigated gene.